Lead Sponsor

Brown University

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Patients are required to have pathologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus, gastroesophageal junction, or stomach.
•Patients may have mediastinal, celiac adenopathy, peri-portal and regional gastric lymphadenopathy.
•There must be no evidence of distant organ metastases.
•No prior radiation for gastric or esophageal cancer.
•Patients must be \> 18 years of age, and nonpregnant
•Patients must have an ANC \> 1,500/ul, platelets \> 100,000/ul, creatinine \< 2 x upper limit normal (ULN) and bilirubin \< 1.5 x ULN, and AST \< 3 x ULN.
•ECOG performance status 0-2.
•Patients must not have significant infection or other coexistent medical condition that would preclude protocol therapy.

•All patients must sign informed consent
•Any of the following criteria will make the patient ineligible to participate in this study:
•Acute hepatitis or AIDS.
•Active or uncontrolled infection.
•Significant history of uncontrolled cardiac disease; i.e., uncontrolled hypertension, unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled congestive heart failure, and cardiomyopathy with decreased ejection fraction.
•Prior therapy which specifically and directly targets the EGFR pathway.
•Prior severe infusion reaction to a monoclonal antibody.
•Any concurrent chemotherapy not indicated in the study protocol or any other investigational agent(s).

Related studies

NCT06713993 · Esophageal Cancer (EsC)

NCT06921928 · Gastric Cancer, Gastroesophageal Junction Cancer, and more

NCT06257264 · Breast Cancer, Small Cell Lung Cancer, and more

NCT07537348 · Advanced Gastric Cancer

NCT06427941 · Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, and more

Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer